Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Identifying proteomic risk factors for cancer using prospective and exome analyses of 1463 circulating proteins and risk of 19 cancers in the UK Biobank

Open access

Abstract

The availability of protein measurements and whole exome sequence data in the UK Biobank enables investigation of potential observational and genetic protein-cancer risk associations. We investigated associations of 1463 plasma proteins with incidence of 19 cancers and 9 cancer subsites in UK Biobank participants (average 12 years follow-up). Emerging protein-cancer associations were further explored using two genetic approaches, cis -pQTL and exome-wide protein genetic scores (exGS). We identify 618 protein-cancer associations, of which 107 persist for cases diagnosed more than seven years after blood draw, 29 of 618 were associated in genetic analyses, and four had support from long time-to-diagnosis ( > 7 years) and both cis -pQTL and exGS analyses: CD74 and TNFRSF1B with NHL, ADAM8 with leukemia, and SFTPA2 with lung cancer. We present multiple blood protein-cancer risk associations, including many detectable more than seven years before cancer diagnosis and that had concordant evidence from genetic analyses, suggesting a possible role in cancer development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-024-48017-6

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Summary of study design, observational and genetic protein-cancer associations, and pathway analyses and drug target mapping. cis-pQTL - cis protein quantitative trait loci, PRS – polygenic risk score, SNP – single nucleotide polymorphism, ENT – effective number of tests. Source data are provided as a Source Data file.
Fig. 1 Summary of study design, observational and genetic protein-cancer associations, and pathway analyses and drug target mapping. cis-pQTL - cis protein quantitative trait loci, PRS – polygenic risk score, SNP – single nucleotide polymorphism, ENT – effective number of tests. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 2 Volcano plot for the prospective associations of circulating proteins with risk of cancer. Volcano plot displaying the results from the prospective observational analyses of 1463 proteins with cancer risk. Top protein-cancer associations plotted with point size indicating the number of ENT significant protein-cancer associations. The point colour represents the cancer site. Hazard ratios per SD for cancer risk are plotted on the x-axis while –log10 p-values are plotted on the y-axis. Protein names and hazard ratios are labelled to highlight a selection of associations significant after correction for multiple testing (p < 0.05/639). Hazard ratios and 95% confidence intervals for each cancer site were separately estimated using two-sided Cox proportional hazards regression models. N- number, ENT – effective number of tests. Source data are provided as a Source Data file.
Fig. 2 Volcano plot for the prospective associations of circulating proteins with risk of cancer. Volcano plot displaying the results from the prospective observational analyses of 1463 proteins with cancer risk. Top protein-cancer associations plotted with point size indicating the number of ENT significant protein-cancer associations. The point colour represents the cancer site. Hazard ratios per SD for cancer risk are plotted on the x-axis while –log10 p-values are plotted on the y-axis. Protein names and hazard ratios are labelled to highlight a selection of associations significant after correction for multiple testing (p < 0.05/639). Hazard ratios and 95% confidence intervals for each cancer site were separately estimated using two-sided Cox proportional hazards regression models. N- number, ENT – effective number of tests. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 3 Volcano plots for the prospective association of circulating proteins with risk of cancer by time to diagnosis. Two volcano plots displaying the results from prospective observational analyses of 1463 proteins with cancer risk stratified by time from blood draw to diagnosis, with analyses among cases diagnosed within three years of blood draw (left) and after seven years of blood draw (right). Top protein-cancer associations plotted with point size indicating the number of ENT significant protein-cancer associations. The point colour represents the cancer site. Hazard ratios for cancer risk per SD are plotted on the x-axis while –log10 p-values are plotted on the y-axis. Protein names and hazard ratios are labelled to highlight a selection of associations significant after correction for multiple testing (p < 0.05/639). Hazard ratios and 95% confidence intervals for each cancer site were separately estimated using two-sided Cox proportional hazards regression models. N- number, ENT – effective number of tests. Source data are provided as a Source Data file.
Fig. 3 Volcano plots for the prospective association of circulating proteins with risk of cancer by time to diagnosis. Two volcano plots displaying the results from prospective observational analyses of 1463 proteins with cancer risk stratified by time from blood draw to diagnosis, with analyses among cases diagnosed within three years of blood draw (left) and after seven years of blood draw (right). Top protein-cancer associations plotted with point size indicating the number of ENT significant protein-cancer associations. The point colour represents the cancer site. Hazard ratios for cancer risk per SD are plotted on the x-axis while –log10 p-values are plotted on the y-axis. Protein names and hazard ratios are labelled to highlight a selection of associations significant after correction for multiple testing (p < 0.05/639). Hazard ratios and 95% confidence intervals for each cancer site were separately estimated using two-sided Cox proportional hazards regression models. N- number, ENT – effective number of tests. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 4 Mirror Manhattan plot for the association of genetically predicted protein concentrations and cancer risk using cis-pQTL and exome scores. This mirror Manhattan plot displays the results of each cis-pQTL (top) in the full exome-sequencing cohort within the UK Biobank across European samples for proteins passing correction for multiple testing in the observational results on cancer risk. The y-axis represents the -log10 p-values. The bottom of this plot contains the exome-wide score results for genetically predicted proteins. Markers coloured in grey represent results that did not reach the conventional p < 0.05 significance threshold, while markers in blue represent conventionally significant results. If a cis-variant or an exome-wide score passes Bonferroni significance, those markers are coloured by the cancer site of association. Odds ratios were estimated using logistic regression models to investigate the association of each genetically predicted protein with cancer risk per standard deviation increase. Cis-variants were adjusted to be on the same scale. cis-pQTL - cis protein quantitative trait loci, NHL – Non-Hodgkin lymphoma. Source data are provided as a Source Data file.
Fig. 4 Mirror Manhattan plot for the association of genetically predicted protein concentrations and cancer risk using cis-pQTL and exome scores. This mirror Manhattan plot displays the results of each cis-pQTL (top) in the full exome-sequencing cohort within the UK Biobank across European samples for proteins passing correction for multiple testing in the observational results on cancer risk. The y-axis represents the -log10 p-values. The bottom of this plot contains the exome-wide score results for genetically predicted proteins. Markers coloured in grey represent results that did not reach the conventional p < 0.05 significance threshold, while markers in blue represent conventionally significant results. If a cis-variant or an exome-wide score passes Bonferroni significance, those markers are coloured by the cancer site of association. Odds ratios were estimated using logistic regression models to investigate the association of each genetically predicted protein with cancer risk per standard deviation increase. Cis-variants were adjusted to be on the same scale. cis-pQTL - cis protein quantitative trait loci, NHL – Non-Hodgkin lymphoma. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 5 The prospective and genetic associations of SFPTA2 with lung cancer risk, CD74 and TNFRSF1B with risk of non-Hodgkin lymphoma, and ADAM8 with risk of leukaemia. Plots show the associations for the four proteins that were associated with the risk of cancer in the main analyses and that had directionally concordant, conventionally significant support from all three additional analyses, i.e., long (>7 years) time-to-diagnosis, cis-pQTL, and exGS analyses. For each protein–cancer association evidence for the association of concentrations with cancer risk is presented from minimally and fully adjusted models per SD, as well as models stratified by time-to-diagnosis, and from exome proteins score and cis-pQTL analyses. The observational analyses (minimally adjusted, fully adjusted models, and time-to-diagnosis analyses were conducted in a maximal sample of 44,645 participants, and the genetic analyses were conducted in a maximal sample of 336,823 UK participants. Data are presented as relative risk and 95% confidence intervals. The reference value is 1.0. cis-pQTL-cis protein quantitative trait loci. Source data are provided as a Source data file.
Fig. 5 The prospective and genetic associations of SFPTA2 with lung cancer risk, CD74 and TNFRSF1B with risk of non-Hodgkin lymphoma, and ADAM8 with risk of leukaemia. Plots show the associations for the four proteins that were associated with the risk of cancer in the main analyses and that had directionally concordant, conventionally significant support from all three additional analyses, i.e., long (>7 years) time-to-diagnosis, cis-pQTL, and exGS analyses. For each protein–cancer association evidence for the association of concentrations with cancer risk is presented from minimally and fully adjusted models per SD, as well as models stratified by time-to-diagnosis, and from exome proteins score and cis-pQTL analyses. The observational analyses (minimally adjusted, fully adjusted models, and time-to-diagnosis analyses were conducted in a maximal sample of 44,645 participants, and the genetic analyses were conducted in a maximal sample of 336,823 UK participants. Data are presented as relative risk and 95% confidence intervals. The reference value is 1.0. cis-pQTL-cis protein quantitative trait loci. Source data are provided as a Source data file.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Cited by

See all 97

Metadata

Authors
Papier, K., Atkins, J. R., Tong, T. Y. N., Gaitskell, K., Desai, T., Ogamba, C. F., Parsaeian, M., Reeves, G. K., Mills, I. G., Key, T. J., Smith-Byrne, K., & Travis, R. C.
Affiliations
  • University of Oxford (GB)
  • Queen's University Belfast (GB)
Corresponding author
Papier, Keren
Venue
Nature Communications
Published
2024-05-15
Volume
15
Issue
1
Pages
4010-4010
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4396929100
Cited by
97
References
50
Citations by year
2026: 39 · 2025: 50 · 2024: 8
FWCI
25.64
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Portal (Queen's University Belfast) (acceptedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Cancer Research UK (C8221/A29017, C8221/A29186)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Physical Sciences › Environmental Science › Health, Toxicology and Mutagenesis › Health, Environment, Cognitive Aging
Keywords
circulating proteins, plasma proteomics, cancer risk, cancer incidence, tumor subtypes, cis-pQTL, CD74, TNF receptor 2, ADAM8, SFTPA2, non-Hodgkin lymphoma, leukemia, lung cancer, early cancer detection, UK Biobank
MeSH terms
Exome Sequencing, UK Biobank, Aged, Blood Proteins, Female, United Kingdom, Humans, Male, Middle Aged, Neoplasms, Prospective Studies, Risk Factors, Incidence, Biological Specimen Banks, Genetic Predisposition to Disease, Proteomics, Exome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identifying proteomic risk factors for cancer using prospective and exome analyses of 1463 circulating proteins and risk of 19 cancers in the UK Biobank. https://app.cochat.ai/papers/10.1038/s41467-024-48017-6
The paper
Papier, K., Atkins, J. R., Tong, T. Y. N., Gaitskell, K., Desai, T., Ogamba, C. F., Parsaeian, M., Reeves, G. K., Mills, I. G., Key, T. J., Smith-Byrne, K., & Travis, R. C. (2024). Identifying proteomic risk factors for cancer using prospective and exome analyses of 1463 circulating proteins and risk of 19 cancers in the UK Biobank. Nature Communications. https://doi.org/10.1038/s41467-024-48017-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.